Alphyn is a life science company developing proprietary drug therapy for treating serious skin diseases. The initial target indication are skin infections caused by deadly drug-resistant MRSA bacteria based on our proprietary Multi-Target Therapeutic (MTT) plant-derived technology platform.
AB-101 is the first topical drug to treat serious skin infections caused by MRSA, Pseudomonas, and other life-threatening multi-drug resistant organisms (MDOs). AB-101 is a complex substance generated by an extensively available tropical plant as its own defense against bacteria Alphyn has significant microbiology data showing AB-101 kills MDOs to which mupirocin, the topical drug of choice, now has up to 80% bacterial resistance. The complex nature of AB-101, with multiple mechanisms that kill bacteria, greatly lessens the chance of drug resistance developing. Our unique regulatory positioning results in significant advantages in reduced time and cost to obtain regulatory approvals.
Alphyn is using its AB-101 platform to apply its therapy-leading Multi-targeted Therapeutics strategy for its first two novel patent-pending topical treatments: one for bacterial skin infections, specifically MRSA Drug Resistant Infections, and 1 for Basal Cell Skin Cancer.
A new prescription-strength topical antibiotic drug that treats MRSA has not been approved since 1987. Current therapies, which are topical, oral and intravenous, are experiencing serious drug resistance problems . Alphyn’s new topical product provides a needed, important first-line weapon to fight bacterial skin infections including those caused by drug-resistant organisms including MRSA.
Current first-line skin cancer therapies, which can be grouped into topical drugs, surgery and skin destruction technologies, all cause some degree of pain, scarring and disfigurement. Alphyn’s new topical product provides effective treatment and is gentle, which means it works without the problems of the current first-line treatments.
Due to the complex variety of active compounds in our AB-101 Multi-targeted Therapeutics platform, Alphyn has an extensive new product pipeline that is targeting skin diseases that currently have poor treatment options.
Neal has been President & CEO and a Director for six life science businesses guiding them to milestone achievement or exit. He began his career at Wyeth Pharmaceuticals where he achieved notable successes in both large division and early stage business responsibilities. Neal has over 30 years as a top executive with a successful history of building, running and growing entrepreneurial and complex global companies.
Steven has over 30 years of experience at Procter & Gamble. At P&G, he was responsible for its $1 billion early-stage technology portfolio and was a global manager of $750 million Beauty Care Products. Post P&G, he held executive responsibility for developing 3 start-up companies and their business exits in the medical device and life sciences areas. Steven has a highly successful track-record in bringing new products to market.
Gary is the Chief Scientific Officer with a PhD in pharmacology. He is a thought leader in infectious diseases and cancer. He spearheaded the approval of Bactroban® (mupirocin), the first and only topical antibiotic drug approved to treat MRSA drug resistant skin infections. Gary has directed multiple pharma/biotech product development programs and founded a strategic regulatory and clinical company focused on early stage innovations. Gary has over 30 years helping develop cutting edge biotechnologies.
Jazmyne is a dynamic scientific researcher who has developed a broad understanding of the mechanisms of plant-derived compounds in the treatment of serious skin diseases.
Alphyn selected to present at the Big Idea CONNECTpreneur Conference, Mid-Atlantic Region.
Chairman & CEO Neal Koller presenting
Alphyn selected to present at BIO International 2019
Alphyn selected to present at CONNECTpreneur Conference Baltimore/Washington DC region
Chairman & CEO Neal Koller presenting
For investment information and details, please contact the company.